CVS Health (NYSE:CVS) Lowered to Hold Rating by Wall Street Zen

CVS Health (NYSE:CVS) was downgraded by investment analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued on Monday.

A number of other equities analysts have also weighed in on the stock. Bank of America upped their price target on shares of CVS Health from $100.00 to $110.00 and gave the stock a “buy” rating in a research report on Monday, June 22nd. JPMorgan Chase & Co. raised their price objective on shares of CVS Health from $101.00 to $111.00 and gave the company an “overweight” rating in a research report on Tuesday, May 12th. Royal Bank Of Canada upped their target price on shares of CVS Health from $93.00 to $107.00 and gave the stock an “outperform” rating in a report on Thursday, May 7th. Wells Fargo & Company increased their price target on CVS Health from $102.00 to $103.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Finally, Morgan Stanley raised their price target on CVS Health from $106.00 to $111.00 and gave the company an “overweight” rating in a report on Thursday, June 4th. Twenty-two investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $101.28.

CVS Health Stock Performance

Shares of CVS opened at $104.38 on Monday. The business has a 50-day simple moving average of $91.81 and a two-hundred day simple moving average of $82.44. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.78. CVS Health has a 52 week low of $58.50 and a 52 week high of $106.15. The stock has a market cap of $133.18 billion, a price-to-earnings ratio of 45.98, a PEG ratio of 1.02 and a beta of 0.62.

CVS Health (NYSE:CVS) last posted its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, beating analysts’ consensus estimates of $2.21 by $0.36. The firm had revenue of $100.43 billion for the quarter, compared to analysts’ expectations of $94.99 billion. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The business’s quarterly revenue was up 6.2% on a year-over-year basis. During the same period in the previous year, the firm earned $2.25 EPS. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. On average, analysts expect that CVS Health will post 7.44 EPS for the current year.

Insider Transactions at CVS Health

In other news, Director Larry Robbins sold 370,462 shares of the company’s stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $93.45, for a total transaction of $34,619,673.90. Following the sale, the director directly owned 4,824,799 shares of the company’s stock, valued at $450,877,466.55. This represents a 7.13% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Tilak Mandadi sold 69,551 shares of the firm’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $89.58, for a total value of $6,230,378.58. Following the completion of the transaction, the executive vice president owned 10,133 shares of the company’s stock, valued at $907,714.14. This trade represents a 87.28% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 3,441,551 shares of company stock worth $323,703,977 over the last quarter. 0.85% of the stock is owned by company insiders.

Institutional Investors Weigh In On CVS Health

A number of large investors have recently bought and sold shares of CVS. Caitong International Asset Management Co. Ltd grew its position in shares of CVS Health by 407.2% in the third quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock valued at $26,000 after purchasing an additional 281 shares during the period. Swiss RE Ltd. acquired a new position in shares of CVS Health during the 4th quarter worth about $26,000. Sankala Group LLC purchased a new position in CVS Health in the 4th quarter valued at about $28,000. Global Trust Asset Management LLC lifted its stake in CVS Health by 344.8% in the 1st quarter. Global Trust Asset Management LLC now owns 387 shares of the pharmacy operator’s stock valued at $28,000 after buying an additional 300 shares in the last quarter. Finally, Mcguire Capital Advisors Inc. acquired a new stake in CVS Health in the 4th quarter worth about $28,000. Hedge funds and other institutional investors own 80.66% of the company’s stock.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.